{"id":"levora","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including LEVORA 0.15/30-28, are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS and WARNINGS (1) ]."],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Breast tenderness","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Cramps","drugRate":"","severity":"common","organSystem":""},{"effect":"Bloating","drugRate":"","severity":"common","organSystem":""},{"effect":"Change in menstrual flow","drugRate":"","severity":"common","organSystem":""},{"effect":"Change in weight","drugRate":"","severity":"common","organSystem":""},{"effect":"Change in appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Breast pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Breast enlargement","drugRate":"","severity":"common","organSystem":""},{"effect":"Breast secretion","drugRate":"","severity":"common","organSystem":""},{"effect":"Vaginitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Candidiasis","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Fluid retention","drugRate":"","severity":"common","organSystem":""},{"effect":"Melasma","drugRate":"","severity":"common","organSystem":""},{"effect":"Chloasma","drugRate":"","severity":"common","organSystem":""},{"effect":"Nervousness","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Mesenteric thrombosis","drugRate":"","severity":"serious"},{"effect":"Serious cardiovascular adverse events","drugRate":"","severity":"serious"},{"effect":"Vascular events","drugRate":"","severity":"serious"},{"effect":"Liver disease","drugRate":"","severity":"serious"},{"effect":"Hypertension","drugRate":"","severity":"serious"},{"effect":"Gallbladder disease","drugRate":"","severity":"serious"},{"effect":"Carcinoma of the cervix","drugRate":"","severity":"serious"},{"effect":"Anaphylactic/anaphylactoid reactions","drugRate":"","severity":"serious"},{"effect":"Budd-Chiari syndrome","drugRate":"","severity":"serious"},{"effect":"Hemolytic uremic syndrome","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1389","moleculeType":"Small molecule","molecularWeight":"312.45"},"aliases":["Hormonal oral contraceptive"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Levora","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:23:58.600903+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:24:05.521032+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levora","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:24:06.322042+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Progesterone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:24:06.903612+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1389/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:24:06.806232+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"31679b9f-58c9-4bf1-8c2c-f5a216ff4cd3","title":"LEVORA (LEVONORGESTREL AND ETHINYL ESTRADIOL) KIT [MAYNE PHARMA INC.]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T01:18:47.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:24:08.821847+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":"Pregnancy, HIV Infections","enrollment":300},{"nctId":"NCT07414784","phase":"PHASE1","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-11","conditions":"Healthy Volunteer","enrollment":20},{"nctId":"NCT07388511","phase":"PHASE1","title":"A Study of Elenestinib in Healthy Adult Female Participants","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2026-02-03","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT06942936","phase":"PHASE1","title":"A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-28","conditions":"Healthy Participants","enrollment":51},{"nctId":"NCT07338955","phase":"","title":"Validating and Assessing Reliability","status":"RECRUITING","sponsor":"Bahria University","startDate":"2025-11-03","conditions":"Upper Limb Disability","enrollment":385},{"nctId":"NCT07010146","phase":"PHASE2","title":"Role of Estrogen on Skeletal Outcomes in FHA","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-07-01","conditions":"Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)","enrollment":150},{"nctId":"NCT03043924","phase":"NA","title":"Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-09-26","conditions":"Polycystic Ovary Syndrome","enrollment":52},{"nctId":"NCT07190430","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT06354257","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-05","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT03249402","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2017-08-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT06671405","phase":"PHASE1","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-25","conditions":"Dyslipidaemia","enrollment":59},{"nctId":"NCT03547024","phase":"PHASE1","title":"A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-06-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT05896384","phase":"PHASE1","title":"A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-12-21","conditions":"Healthy","enrollment":32},{"nctId":"NCT06799884","phase":"PHASE1","title":"A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2025-01-18","conditions":"Drug Drug Interaction","enrollment":19},{"nctId":"NCT06657105","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06783192","phase":"PHASE1","title":"A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-14","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":14},{"nctId":"NCT05058872","phase":"PHASE4","title":"Contraceptive Hormone and Reward Measurement (CHARM Study)","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-10-01","conditions":"Oral Hormonal Contraceptive Use, Neural Activity, Mood","enrollment":144},{"nctId":"NCT03557619","phase":"PHASE1","title":"A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2019-07-30","conditions":"Hematologic Malignancies","enrollment":12},{"nctId":"NCT05093205","phase":"PHASE1","title":"STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-25","conditions":"Healthy Adults","enrollment":35},{"nctId":"NCT06380205","phase":"PHASE1","title":"A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-05-07","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT02616146","phase":"PHASE3","title":"Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2015-12-01","conditions":"Contraception","enrollment":2016},{"nctId":"NCT03745144","phase":"PHASE1","title":"Effects of Cladribine Tablets on the PK of Microgynon®","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2019-01-17","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":28},{"nctId":"NCT05153564","phase":"PHASE1","title":"A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-13","conditions":"Diabetes Mellitus, Type 2","enrollment":27},{"nctId":"NCT05613777","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-11-24","conditions":"Healthy","enrollment":19},{"nctId":"NCT03630159","phase":"PHASE1","title":"Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-09","conditions":"Diffuse Large B-cell Lymphoma","enrollment":12},{"nctId":"NCT00511355","phase":"PHASE3","title":"Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":121},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":"HIV, Immune Cells (Mucosal and Systemic), Contraception","enrollment":326},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT00447863","phase":"PHASE1","title":"Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-08","conditions":"Contraception","enrollment":""},{"nctId":"NCT04194905","phase":"PHASE1","title":"Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2020-11-21","conditions":"Bioequivalence","enrollment":10},{"nctId":"NCT01116440","phase":"PHASE2","title":"A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis","status":"TERMINATED","sponsor":"Mereo BioPharma","startDate":"2010-04-15","conditions":"Pelvic Pain Associated With Refractory Endometriosis","enrollment":27},{"nctId":"NCT03675581","phase":"PHASE1","title":"A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-08","conditions":"Scleroderma, Systemic","enrollment":17},{"nctId":"NCT00662454","phase":"PHASE4","title":"Oral Contraceptive Efficacy and Body Weight","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-01","conditions":"Contraception, Body Weight","enrollment":120},{"nctId":"NCT03984825","phase":"PHASE1","title":"Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-06-13","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT04309643","phase":"PHASE1","title":"Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2020-06-09","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT03662516","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-26","conditions":"Healthy Females","enrollment":17},{"nctId":"NCT04142762","phase":"PHASE1","title":"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2019-10-18","conditions":"Chronic Hepatitis B","enrollment":80},{"nctId":"NCT02922127","phase":"PHASE1","title":"Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-12-16","conditions":"Contraception","enrollment":29},{"nctId":"NCT04134715","phase":"PHASE1","title":"A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-23","conditions":"Healthy","enrollment":15},{"nctId":"NCT02577601","phase":"PHASE4","title":"Impact of Combined Hormonal Contraceptives on UPA","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-09-08","conditions":"Contraception","enrollment":36},{"nctId":"NCT01953211","phase":"","title":"Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity","status":"COMPLETED","sponsor":"University of Southern California","startDate":"","conditions":"Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy","enrollment":64},{"nctId":"NCT02531321","phase":"PHASE4","title":"Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2015-08","conditions":"Contraception, HIV","enrollment":17},{"nctId":"NCT00827632","phase":"PHASE4","title":"Obesity, Oral Contraception, and Ovarian Suppression","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-07","conditions":"Ovarian Suppression","enrollment":226},{"nctId":"NCT02751385","phase":"PHASE1","title":"Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2016-05-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":2},{"nctId":"NCT03210246","phase":"PHASE1","title":"Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-17","conditions":"Clinical Trial ,Phase I","enrollment":71},{"nctId":"NCT02404038","phase":"NA","title":"A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2015-07","conditions":"HIV","enrollment":131},{"nctId":"NCT01250210","phase":"PHASE2","title":"Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2007-09","conditions":"Ovulation Suppression","enrollment":123},{"nctId":"NCT01181479","phase":"PHASE3","title":"Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-08","conditions":"Contraception","enrollment":1504},{"nctId":"NCT03506399","phase":"PHASE1","title":"A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2018-06","conditions":"Healthy","enrollment":""},{"nctId":"NCT02846142","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Proteostasis Therapeutics, Inc.","startDate":"2016-06","conditions":"Healthy Volunteer","enrollment":94},{"nctId":"NCT00310791","phase":"PHASE2, PHASE3","title":"Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2004-04","conditions":"Anorexia Nervosa","enrollment":80},{"nctId":"NCT01941134","phase":"PHASE4","title":"Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Bariatric Surgery Candidate, Contraception","enrollment":""},{"nctId":"NCT03359057","phase":"PHASE3","title":"Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel","status":"COMPLETED","sponsor":"Galeno Desenvolvimento de Pesquisas Clínicas","startDate":"2013-02-26","conditions":"Contraception","enrollment":36},{"nctId":"NCT01236768","phase":"PHASE3","title":"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-10","conditions":"Contraception","enrollment":407},{"nctId":"NCT00213096","phase":"PHASE2","title":"Effects of Hormonal Contraceptives on Liver Proteins and Coagulation Factors: A Comparison of a Contraceptive Vaginal Ring and an Oral Contraceptive","status":"COMPLETED","sponsor":"Population Council","startDate":"2003-03","conditions":"Contraception","enrollment":50},{"nctId":"NCT02845219","phase":"PHASE1","title":"A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT01896726","phase":"PHASE1","title":"A Study of Baricitinib and Birth Control Pills in Healthy Females","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT01963403","phase":"PHASE4","title":"Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2013-12","conditions":"Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy","enrollment":26},{"nctId":"NCT01546454","phase":"NA","title":"Relationship Between the Menstrual Cycle and Heart Disease in Women","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-02","conditions":"Coronary Heart Disease","enrollment":5},{"nctId":"NCT00781456","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2009-01","conditions":"Migraine","enrollment":109},{"nctId":"NCT01165307","phase":"PHASE4","title":"Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia","status":"COMPLETED","sponsor":"Abimbola Famuyide","startDate":"2009-08","conditions":"Menorrhagia","enrollment":77},{"nctId":"NCT02599077","phase":"PHASE2, PHASE3","title":"Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas","status":"SUSPENDED","sponsor":"Fundación Santa Fe de Bogota","startDate":"2015-11","conditions":"Endometriosis","enrollment":50},{"nctId":"NCT00196326","phase":"PHASE3","title":"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-06","conditions":"Contraception","enrollment":2235},{"nctId":"NCT01615354","phase":"PHASE1","title":"A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT00196313","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-05","conditions":"Dysmenorrhea","enrollment":95},{"nctId":"NCT00511784","phase":"","title":"Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Contraception, Female Contraception, Fertility Control","enrollment":440},{"nctId":"NCT01941615","phase":"PHASE1","title":"Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT01501448","phase":"PHASE4","title":"Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2012-01","conditions":"Infertility","enrollment":118},{"nctId":"NCT02641990","phase":"PHASE1","title":"Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2015-12","conditions":"Healthy Adult Premenopausal Female Volunteers","enrollment":28},{"nctId":"NCT01480778","phase":"PHASE3","title":"Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2014-07","conditions":"Irregular Periods","enrollment":62},{"nctId":"NCT02170038","phase":"PHASE1","title":"Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06","conditions":"Pharmacokinetics","enrollment":16},{"nctId":"NCT01170390","phase":"PHASE4","title":"Oral Contraceptives and Body Mass Index","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-09","conditions":"Body Weight, Contraceptive Usage","enrollment":32},{"nctId":"NCT00920985","phase":"PHASE3","title":"US Cycle Control and Blood Pressure Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-06","conditions":"Contraception","enrollment":346},{"nctId":"NCT00909857","phase":"PHASE3","title":"Effect on Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04","conditions":"Primary Dysmenorrhea","enrollment":507},{"nctId":"NCT02159326","phase":"PHASE1","title":"Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06","conditions":"Drug Interactions","enrollment":31},{"nctId":"NCT02385448","phase":"PHASE4","title":"Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2015-02","conditions":"Endometriosis","enrollment":144},{"nctId":"NCT01252186","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2010-11","conditions":"Hemostasis, Oral Contraceptive","enrollment":265},{"nctId":"NCT00764881","phase":"PHASE3","title":"Effects of SH T00658ID on Libido","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Contraception, Libido","enrollment":217},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00933179","phase":"PHASE2","title":"FC Patch Low: Metabolism Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-06","conditions":"Contraception","enrollment":30},{"nctId":"NCT00480532","phase":"NA","title":"A Study of Continuous Oral Contraceptives and Doxycycline","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptives, Oral","enrollment":131},{"nctId":"NCT00924560","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2009-06","conditions":"Bone Mineral Density","enrollment":1361},{"nctId":"NCT02175394","phase":"PHASE1","title":"Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07","conditions":"Healthy","enrollment":18},{"nctId":"NCT01328184","phase":"PHASE1","title":"Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT00196365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-01","conditions":"Dysmenorrhea","enrollment":97},{"nctId":"NCT00117273","phase":"PHASE3","title":"A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT00196352","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2003-05","conditions":"Contraception","enrollment":320},{"nctId":"NCT00117260","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Seasonale for Treatment of Low Bone Mineral Density","status":"WITHDRAWN","sponsor":"Duramed Research","startDate":"2005-07","conditions":"Osteopenia","enrollment":""},{"nctId":"NCT00394771","phase":"PHASE2","title":"A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2006-10","conditions":"Breakthrough Bleeding","enrollment":567},{"nctId":"NCT01297348","phase":"","title":"Study Of Lybrel In Relation To Venous Thromboembolism","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Venous Thrombosis, Pulmonary Embolism, Sinus Thrombosis, Intracranial","enrollment":598682},{"nctId":"NCT00996580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2009-10","conditions":"Pregnancy Prevention","enrollment":3597},{"nctId":"NCT01569113","phase":"PHASE4","title":"Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2012-03","conditions":"Emergency Contraception","enrollment":76},{"nctId":"NCT00161681","phase":"PHASE3","title":"Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-07","conditions":"Premenstrual Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1389"},"formularyStatus":[],"_approvalHistory":[{"date":"19960610","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20170724","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20220429","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20010816","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"19931213","type":"ORIG","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"19960710","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20220307","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20170809","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20140207","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"20220307","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"},{"date":"19961031","type":"SUPPL","sponsor":"DR REDDYS LABS SA","applicationNumber":"ANDA073594"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Levora","genericName":"Levora","companyName":"Agile Therapeutics","companyId":"agile-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:24:08.821847+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}